Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Subtype terms (15)
More specific conditions that are subtypes of Neoplasms in the MeSH hierarchy.
- Cysts
5 drugs (3 approved, 2 experimental)
- Hamartoma
446 drugs (186 approved, 260 experimental)
- Neoplasms by Histologic Type
70 drugs (49 approved, 21 experimental)
- Neoplasms by Site
75 drugs (41 approved, 34 experimental)
- Neoplasms, Experimental
2 drugs (1 approved, 1 experimental)
- Neoplasms, Hormone-Dependent
4 drugs (3 approved, 1 experimental)
- Neoplasms, Multiple Primary
3 drugs (2 approved, 1 experimental)
- Neoplasms, Post-Traumatic
- Neoplasms, Radiation-Induced
- Neoplasms, Second Primary
29 drugs (25 approved, 4 experimental)
- Neoplastic Processes
2 drugs (1 approved, 1 experimental)
- Neoplastic Syndromes, Hereditary
14 drugs (13 approved, 1 experimental)
- Paraneoplastic Syndromes
1 drug approved
- Precancerous Conditions
132 drugs (94 approved, 38 experimental)
- Pregnancy Complications, Neoplastic
Drugs by status
Approved for this indication (102)
- irradiated donor lymphocyte
- altretamine
- entrectinib
- sodium phenylbutyrate
- morphine
- nedaplatin
- palonosetron
- pirarubicin
- haploidentical mononuclear cells
- oteracil
- metoclopramide
- donafenib
- hydrocortisone
- sodium dichloroacetate
- chidamide
- bone marrow derived mesenchymal stem cells
- xiaoai jiedu decoction
- huaier
- methylene blue
- talotrexin
- thiopurine
- vindesine
- cinobufacin
- recombinant adenoviral human p53 gene
- octreotide
- pyrotinib
- tislelizumab
- aprepitant
- repotrectinib
- eflapegrastim
- +72 more
Phase 4 trials (160)
- ribavirin
- sorafenib
- ribociclib
- atenolol
- metformin
- vitamin d3
- bnt162b2
- denosumab
- dronabinol
- atezolizumab
- bifidobacterium bifidum
- lacosamide
- multivitamins
- dactinomycin
- epinephrine
- oxygen
- amifostine
- sodium chloride
- pegloticase
- cobicistat
- rivaroxaban
- polyethylene glycol
- human papillomavirus 9-valent vaccine, recombinant
- clopidogrel
- cocoa bean
- oxaliplatin
- sevoflurane
- dalteparin
- bleomycin
- in111-octreoscan
- +130 more
Phase 3 trials (267)
- polihexanide
- modafinil
- onabotulinumtoxinA
- oxymorphone
- beta-glucans
- ferric sulfate
- 177lu-dota0-tyr3-octreotate
- n-(4-hydroxyphenyl)all-trans retinamide
- etanercept
- vitamin c
- xingzaoruanjian
- retifanlimab
- thiamine
- COVID-19 convalescent plasma
- ivabradine
- temozolomide
- watercress
- icotinib
- ginseng
- olanzapine
- fosfomycin
- pf-04518600
- lenzilumab
- dacarbazine
- palivizumab
- ctx-009
- efaproxiral
- sulfur hexafluoride lipid-type a microspheres
- talc
- tumor-pulsed dendritic cells
- +237 more
Phase 2 trials (1521)
- trabectedin
- [18f]fpygal
- adh-1
- cd7 car-t cell
- uncaria tomentosa
- lutetium dotatate lu-177
- lmb-100
- dendritic cells loaded with 17 antigens
- bms-777607
- pocenbrodib
- monoclonal antibody cal
- ima950
- sheng bai
- 3hp-2827
- cfi-402257
- ivermectin
- db-1305
- oc-001
- bms-986277
- t lymphocytes
- rec-1245
- imc-f106c
- aroplatin
- jab-23e73
- antineoplaston a10
- ga-68-dota-toc
- jdq443
- humax-il8
- shr-a1912
- dalpiciclib
- +1491 more
Phase 1 trials (2583)
Other trials (299)
- aflibercept
- cirmtuzumab
- rucaparib
- [18f]rccb6
- avn-944
- rhizoma dioscoreae
- ibrutinib
- propionibacterium acnes
- 131 i-omburtamab
- amsacrine
- guadecitabine
- clevudine
- fulvestrant
- celecoxib
- gadobenate
- actinosynbacter
- coronavac
- cetuximab
- cloxacillin
- nivolumab
- hesperidin
- [68ga]ga-nota-rnd20
- temsirolimus
- gadofosveset trisodium
- Efbemalenograstim alpha
- valdecoxib
- rituximab
- 18f-dx600
- nintedanib
- soybean
- +269 more
Organizations
Organization Involved with Phase 4 Indications (75)
- University of London
- Orebro University
- Bausch Health Companies
- Arbeitsgemeinschaft fur Internistische Onkologie (AIO)
- Shijiazhuang Pharma Group (CSPC)
- National Cancer Institute (NCI)
- Shandong University
- OSF HealthCare
- Providence Health & Services
- Shenzhen SiBiono GeneTech Co.,Ltd
- University of Amsterdam
- University of Washington
- Chinese Academy of Medical Sciences
- Institutul Clinic Fundeni, Bucarest, Romania
- University of Florida
- Roche
- Chonnam National University
- Kalmar County Hospital
- Fraser Health
- Inonu University
- Helsingborgs Hospital
- Saint-Petersburg State Medical University
- Sanofi
- University of Oklahoma
- University of Illinois
- Lund University
- Sun Yat-Sen University
- Air Liquide
- Luye Pharma
- The University of Hong Kong
- +45 more
Organization Involved with Phase 3 Indications (225)
- University of Alabama, Birmingham
- Genzyme
- AryoGen Pharmed Co.
- Medical University of Vienna
- Leiden University
- People's Liberation Army of China
- Queen's University, Belfast
- Italian Association for Pediatric Hematology Oncology
- Abbott
- Tanta University
- NSABP Foundation
- University of Southern Denmark
- Hebrew University
- Genentech
- Cancer and Leukemia Group B (CALGB)
- University of Ankara
- University of Melbourne
- University of Birmingham
- Emory University
- Sint Franciscus Gasthuis
- Vanderbilt University
- GlaxoSmithKline
- GTx
- Government of Japan
- Institut Gustave Roussy
- Meander Medical Center
- Gynecologic Oncology Group
- Movember Foundation
- Harvard University
- Government of Brazil
- +195 more
Organization Involved with Phase 2 Indications (600)
- University of Illinois at Chicago
- University of Cambridge
- Centre Henri Becquerel
- Jiangsu vcare pharmaceutical technology co., LTD
- Government of Singapore
- University of Nebraska
- Hoag Memorial Hospital Presbyterian
- Government of Taiwan
- Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
- Central South University
- Kiadis Pharma
- Swedish Orphan Biovitrum
- Catholic University of Sacred Heart, Rome
- University of Regensburg
- Gruppo Italiano Trapianto di Midollo Osseo
- University of South Florida
- Clovis Oncology
- Taiwan Liposome Company
- University Clermont Auvergne
- National Cancer Institute, France
- service Hématologie Séniors Hôpital Saint Louis
- Ningbo No. 5 Hospital
- University of Bologna
- Acetylon Pharmaceuticals Incorporated
- Lyndhurst Gynecologic Associates
- TetraLogic Pharmaceuticals
- MolMed S.p.A.
- Accenture
- Miami Cancer Institute
- Tesaro
- +570 more
Organization Involved with Phase 1 Indications (520)
- Harbour BioMed Co. Ltd.
- Leadiant Biosciences, Inc.
- Lawrence Livermore National Laboratory
- Henlix, Inc
- Jeil Pharmaceutical Co., Ltd.
- KCRN Research
- NCC Hospital
- Guangzhou FineImmune Biotechnology Co., LTD.
- Hokkaido University
- Huabo Biopharm Co., Ltd.
- Kantonsspital Graubünden
- CRC Malaysia
- START Midwest
- Synta Pharmaceuticals Corp.
- A*Star
- Medivation
- Traslational Cancer Drugs Pharma, SL
- Open Innovation Partners
- Cancer Trials Ireland
- Vasgene Therapeutics, Inc
- Nippon Shinyaku Co Ltd
- Isarna Therapeutics GmbH
- Bliss Biopharmaceutical Co., Ltd
- Hebei Senlang Biotechnology Inc., Ltd.
- CMG Pharmaceutical Co. Ltd
- Piramal
- James B. and Lois R. Archer Charitable Foundation
- Avera Health
- SymBio Pharmaceuticals
- Shionogi
- +490 more
Organization Involved with Other Experimental Indications (36)
- Chang Gung University
- Istanbul University
- University of Nottingham
- Eastern Regional Medical Center
- Quadram Institute
- Ride for Kids
- Institut Pasteur
- University of Geneva
- Narayana Hrudayalaya Limited
- Advent Health
- Trinity College Dublin
- Cerbaliance
- University of Freiburg
- Leukosite
- Innovive Pharmaceuticals
- King Faisal Specialist Hospital
- Regional Cancer Center, Trivandrum, India
- Alberta Cancer Foundation
- King Faisal University
- Institute of Food Research, Norwich
- Clinical Trial Center Maastricht
- Fundacion SEIMC-GESIDA
- Borstkanker Onderzoek Groep
- Amrita Institute of Medical Sciences
- Mashhad University of Medical Sciences
- Children's Cancer Research Fund United States
- University of Bristol
- Upstate Carolina
- Naestved Hospital
- American Society of Clinical Oncology
- +6 more